Dabigatran, n=32 Warfarin, n=31 p-value
ADAS ADAS ADAS ADAS
Baseline score among all participants, n=91
Mean±SD 13.7±5.8 13.1±5.7 0.61
Median 13.7 11.8 0.44
Baseline score among participants completing study, n=63
Mean±SD 13.2±5.4 12.1±5.0 0.41
Median 13.3 11.3 0.27
24-month scores
Mean±SD 11.4±7.0 10.0±6.7 0.42
Median 8.7 8.7 0.60
Percent change from baseline to 24-months
Mean±SD -12.4±38.3% -21.2±30.3% 0.32
Median -11.5% -23.5% 0.52
DAD DAD DAD DAD
Baseline score among all participants, n=92
Mean±SD 40.6±1.0 40.9±0.4 0.05
Median 41.0 41.0 0.06
Baseline score among participants completing study, n=63
Mean±SD 40.6±1.1 40.9±0.4 0.18
Median 41.0 41.0 0.24
24-month scores
Mean±SD 40.7±0.8 40.7±0.9 0.80
Median 41.0 41.0 0.35
Percent change from baseline to 24-months
Mean±SD 0.22±3.33 -0.38±2.47 0.42
Median 0 0 0.74
HIS HIS HIS HIS
Baseline score among all participants, n=96
Mean±SD 1.36±0.99 1.41±0.96 0.82
Median 1.00 1.00 0.82
Baseline score among participants completing study, n=63
Mean±SD 1.44±0.84 1.42±0.99 0.94
Median 1.00 1.00 0.75
24-month scores
Mean±SD 1.44±0.72 1.50±1.04 0.78
Median 1.00 1.00 0.81
Percent change from baseline to 24-months
Mean±SD 4.3±8.9% 2.6±8.3% 0.43
Median 3.4% 0% 0.56
MMSE MMSE MMSE MMSE
Baseline score among all participants, n=96
Mean±SD 27.4±2.7 27.7±2.2 0.51
Median 28.0 28.0 0.82
Baseline score among participants completing study, n=63
Mean±SD 27.7±2.2 27.8±2.3 0.88
Median 28.0 28.0 0.81
24-month scores
Mean±SD 28.8±1.8 28.4±1.8 0.39
Median 29.0 29.0 0.28
Percent change from baseline to 24-months
Mean±SD 7.3±46.9% 5.9±27.4% 0.89
Median 0% 0% 0.50